Stock Market Reviews

GRAL (GRAIL, Inc.) News

Get the latest news, insights, and market updates on GRAL (GRAIL, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Stock Of The Day: Why IBD 50's Guardant Health Has Rallied 31% In A Month
  Guardant Health stock broke out of a cup base as enthusiasm builds for the company's new blood test, Shield MCD.
  Oct 20, 2025 - $GRAL
• /U P D A T E -- GRAIL, Inc./
  GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.
  Oct 18, 2025 - $GRAL
• Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show
  Grail shared the results of it Pathfinder 2 study during a meeting of the European Society for Medical Oncology in Berlin on Saturday.
  Oct 18, 2025 - $GRAL
• Samsung entities, Grail to roll out early cancer detection test in Asia
  The entities have committed to an investment of $110m (Won156.58bn) in Grail, with the purchase price set at $70.05 per share of common stock.
  Oct 17, 2025 - $GRAL
• GRAIL (GRAL) Is Up 21.5% After Samsung Partnership to Expand Galleri Test in Asia – What's Changed
  Samsung C&T and Samsung Electronics announced a US$110 million equity investment in GRAIL and a collaboration to commercialize the Galleri multi-cancer detection test in key Asian markets, with initial distribution exclusively in South Korea and potential expansion to Japan and Singapore. This partnership brings together GRAIL’s technology and Samsung’s commercial strength, while also opening the door for further integration of health data platforms and joint research initiatives. We’ll...
  Oct 17, 2025 - $GRAL
• GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
  GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.
  Oct 17, 2025 - $GRAL
• Why Grail Stock Soared 14% Higher on Thursday
  The company is receiving a significant equity investment as a component of a collaboration agreement with a large business partner.
  Oct 16, 2025 - $GRAL